申石生物医药

Shenshi Biotech is a clinical-stage biopharmaceutical company based in Shanghai, China, dedicated to developing innovative cell therapies for the treatment of solid tumors. The company focuses on overcoming the immunosuppressive tumor microenvironment through advanced genetic engineering of CAR-T and TCR-T cells. Their lead candidate, SS-001, is a GPC3-targeted CAR-T therapy currently being evaluated for safety and efficacy in patients with advanced hepatocellular carcinoma. By leveraging proprietary technology platforms, Shenshi Biotech aims to transform the landscape of cancer immunotherapy for high-unmet-need indications. The company operates within the Zhangjiang Hi-Tech Park, benefiting from a robust ecosystem of biotechnology research and development.